| 摘要 |
The present application discloses an acid labile lipophilic molecular conjugate (ALLMC) of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof The ALLMC has the formula of the formula 1, or 1.1: (see formula 1) ( see formula 1.1) wherein: R is a hydroxyl bearing cancer chemotherapeutic agent selected from the group consisting of taxanes, abeo-taxanes, camptothecins, epothilones, cucurbitacins, quassinoids, anthracyclines, aclarubicin, camptothecin, masoprocol, paclitaxel, pentostatin, amrubicin, cladribine, cytarabine, docetaxel, elliptinium acetate, epirubicin, etoposide, formestane, fulvestrant, gemcitabine, idarubicin, pirarubicin, topotecan, valrubicin and vinblastine; R1 is hydrogen, C1-C4 alkyl or C5-C22 alkyl; R2 is C5-C22 alkyl; Y is selected from O, NR' or S wherein R' is hydrogen or C1-C6 alkyl; Z is O or S; Q is O or S; and T is O or S; or their isolated enantiomers, diastereoisomers or mixtures thereof; or a pharmaceutically acceptable salt thereof |
